Shandong Weigao Group Medical Polymer Company Limited (“Weigao Group”) disclosed on 7 October 2026 that it repurchased 143,200 H-shares on the Hong Kong Stock Exchange the same day, spending HK$0.46 million at prices ranging from HK$3.225 to HK$3.25 per share (volume-weighted average price: HK$3.2383).

Following the transaction:

• Outstanding H-shares (excluding treasury shares) fell marginally by 0.0032% to 4,455.41 million. • Treasury shares rose to 66.92 million from 66.78 million. • Total issued shares remained unchanged at 4,522.33 million, as the repurchased shares are being held in treasury rather than cancelled.

The buyback forms part of the mandate approved on 29 May 2026, which authorises Weigao Group to repurchase up to 446.46 million shares. Including the latest purchase, the company has acquired 9.60 million shares under this mandate, equivalent to 2.15% of the shares outstanding on the authorization date.

Under Hong Kong Listing Rules, Weigao Group is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares following the 7 October transaction, lasting until 7 November 2026.